期刊
FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.627693
关键词
theranostics (combined therapeutic and diagnostic technology); breast cancer subtypes; molecular imaging; targeted therapy; preclinical (in-vivo) studies; positron emission tomography; single-photon emission computed tomography
资金
- China Scholarship Council [201906160034]
Breast cancer, the most common cancer in women globally, presents challenges in diagnosis and treatment due to its heterogeneity and drug resistance. Molecular imaging methods offer precision medicine tools, while new therapeutic targets and options are being developed to overcome resistance to standard treatments for breast cancer patients.
Breast cancer is the most common cancer in women worldwide. The heterogeneity of breast cancer and drug resistance to therapies make the diagnosis and treatment difficult. Molecular imaging methods with positron emission tomography (PET) and single-photon emission tomography (SPECT) provide useful tools to diagnose, predict, and monitor the response of therapy, contributing to precision medicine for breast cancer patients. Recently, many efforts have been made to find new targets for breast cancer therapy to overcome resistance to standard of care treatments, giving rise to new therapeutic agents to offer more options for patients with breast cancer. The combination of diagnostic and therapeutic strategies forms the foundation of theranostics. Some of these theranostic agents exhibit high potential to be translated to clinic. In this review, we highlight the most recent advances in theranostics of the different molecular subtypes of breast cancer in preclinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据